Multivessel Coronary Artery Disease: Bypass Surgery. Bruce Lytle, MD
|
|
- Ashlyn Little
- 7 years ago
- Views:
Transcription
1 Multivessel Coronary Artery Disease: Bypass Surgery Bruce Lytle, MD
2 Coronary Artery Bypass Surgery Prolongs Survival Angiographic Subgroups MR (%) LMT stenosis (> 50%) 68% 3V CAD (> 50%) 42% 1/2V CAD and proximal LAD (> 50%) 32% no proximal LAD -5%
3 Coronary Artery Bypass Surgery Prolongs Survival The more severe the coronary disease, symptoms, and LV dysfunction, the greater the survival benefit of surgery over medical therapy.
4 Coronary Artery Bypass Surgery Improves Quality of Life Independent of Severity of CAD Angina Increase in exercise capacity Decrease in antianginal medications
5 Randomized Studies versus Mostly low risk patients Mostly normal LV function Mostly 2 vessel CAD Insufficient numbers of patients with extensive CAD
6 Cumulative Event Rate (%) MACCE to 4 Years 3VD Subset 50 Before 1 year * 11.5% vs 19.2% P 1-2 years * 4.4% vs 7.0% P= years * 4.6% vs 7.4% P= years * 2.8% vs 7.7% P P TAXUS (N=546) 33.7% % (N=549) Months Since Allocation Cumulative KM Event Rate ± 1.5 SE; log-rank P value; * Binary rates ITT population
7 Cumulative Event Rate (%) All-Cause Death to 4 Years 3VD Subset 50 Before 1 year * 2.9% vs 4.5% P= years * 1.2% vs 2.1% P= years * 1.7% vs 3.2% P= years * 1.7% vs 2.5% P=0.40 P= TAXUS (N=546) 11.9% Months Since Allocation (N=549) 7.3% Cumulative KM Event Rate ± 1.5 SE; log-rank P value; * Binary rates ITT population
8 Cumulative Event Rate (%) Repeat Revascularization to 4 Years 3VD Subset 50 Before 1 year * 5.5% vs 14.6% P 1-2 years * 2.8% vs 3.9% P= years * 2.5% vs 3.0% P= years * 0.6% vs 4.4% P P 25 TAXUS (N=546) 22.8% 10.2% Months Since Allocation (N=549) Cumulative KM Event Rate ± 1.5 SE; log-rank P value; * Binary rates ITT population
9 Cumulative Event Rate (%) Myocardial Infarction to 4 Years 3VD Subset 50 Before 1 year * 2.7% vs 5.2% P= years * 0.2% vs 1.2% P= years * 0.4% vs 1.0% P= years * 0.0% vs 2.3% P=0.001 P 25 (N=549) TAXUS (N=546) 9.0% 0 3.3% Months Since Allocation Cumulative KM Event Rate ± 1.5 SE; log-rank P value; * Binary rates ITT population
10 Cumulative Event Rate (%) CVA to 4 Years 3VD Subset 50 Before 1 year * 1.9% vs 0.7% P= years * 0.4% vs 0.8% P= years * 0.6% vs 0.8% P= years * 0.4% vs 0.2% P=0.62 P= (N=549) TAXUS (N=546) 3.4% 2.8% Months Since Allocation Cumulative KM Event Rate ± 1.5 SE; log-rank P value; * Binary rates ITT population
11 Cumulative Event Rate (%) MACCE to 4 Years by SYNTAX Score Tercile Intermediate Scores (23-32) 3-vessel Disease P value 50 P= TAXUS (N=207) 33.3% Death 12.4% 18.6% CVA 3.6% 2.5% MI 3.1% 10.5% % (N=208) Months Since Allocation Death, CVA or MI 12.4% 18.6% 0.09 Revasc. 8.3% 21.0% Cumulative KM Event Rate ± 1.5 SE; log-rank P value Site-reported Data; ITT population
12 Cumulative Event Rate (%) MACCE to 4 Years by SYNTAX Score Tercile High Scores ( 33) 50 3-vessel Disease P= % TAXUS (N=155) P value Death 6.5% 14.5% 0.02 CVA 2.6% 5.1% % (N=166) Months Since Allocation MI 1.9% 7.9% 0.01 Death, CVA or MI 11.0% 22.3% Revasc. 11.2% 26.7% Cumulative KM Event Rate ± 1.5 SE; log-rank P value Site-reported Data; ITT population
13 ASCERT Trial 2/3 V CAD: ,793 Total
14 Proportion Surviving IPW Adjusted Survival 1.0 Age >75 Age < RR =.77 at 4 years 0.6 RR =.78 at 4 years ,000 1, ,000 1,500 Days from Index Procedure
15 Proportion Surviving IPW Adjusted Survival 1.0 Men Women RR =.81 RR = ,000 1, ,000 1,500 Days from Index Procedure
16 Proportion Surviving IPW Adjusted Survival 1.0 No Diabetes Diabetes: No Insulin Diabetes: Insulin RR =.81 RR =.78 RR = ,000 1, ,000 1, ,000 1,500 Days from Index Procedure
17 Proportion Surviving IPW Adjusted Survival 1.0 EF<30 EF EV> RR =.70 RR =.70 RR = ,000 1, ,000 1, ,000 1,500 Days from Index Procedure
18 Proportion Surviving IPW Adjusted Survival 1.0 GFR<30 GFR GFR> RR = ,000 1,500 RR =.79 RR = ,000 1, ,000 1,500 Days from Index Procedure
19 Emilia-Romagna Registries July 2002 Dec 2008 (REAL) 6246 (RERIC) Surgery 5504 Excluded STEMI, Previous Revasc All had either LMCA, Two other vessels or both
20 Cumulative rate of Death (%) and DES only in Propensity Score Matched Sample Death DES Months
21 Hazard Ratio of Death at Five-years Subgroups No. deaths/total no. (%) Hazard ratio (95% CI) P valve Overall Age <55 yr >55 yr Sex Female Male No. vessles diseased 1 with LMCA 2. Without LMCA 2. With LMCA 3. Wihtout LMCA 3. With LMCA LEVF >36% <35% Previous MI No Yes CHF No Yes Diabetes No Yes CVD No Yes CRF No Yes COPD No Yes Malignancy No Yes 587/2702 (20.3) 90/967 (9.3) 470/1,776 (36.5) 142/614 (23.1) 410/2.128 (19.3) 21/65 (32.3) 101/671 (15.1) 80/269 (29.7) 272/1407 (19.3) 70/154 (45.5) 501/2583 (19.4) 73/154 (45.5) 330/1,891 (17.5) 252/611 (31.1) 347/2.204 (15.7) 215/523 (41.1) 352/1,998 (17.8) 219/730 (30.0) 445/2,392 (15.7) 105/364 (28.8) 483/2,581 (15.7) 75/139 (54.0) 457/2,508 (15.2) 86/222 (35.7) 511/2,636 (10.4) 45/108 (42.8) 422/2,762 (15.3) 69/967 (7.1) 361/1776 (20.3) 109\614 (17.8) 314/2,128 (14.8) 17/65 (26.2) 99/671 (14.8) 51/269 (19.0) 198/1407 (14.1) 36/154 (23.4) 376/2,583 (14.6) 43/142 (30.3) 228/1,891 (12.1) 163/811 (22.6) 267/2,204 (12.1) 144/523 (27.5) 272/1,998 (13.6) 151/730 (20.7) 355/2,392 (13.9) 88/364 (24.2) 355/2,581 ( /130 (37.4) 34/2,506 (13.6) 70/222 (31.5) 1.55 ( ) 1.52 ( ) 1.56 ( ) 1.59 ( ) 1.52 ( ) 1.37 ( ) 1.21 ( ) 1.96 ( ) 1.51 ( ) 2.49 ( ) 1.59 ( ) 2.24 ( ) 1.71 ( ) 1.66 ( ) 1.57 ( ) 1.85 ( ) 1.49 ( ) 1.78 ( ) 1.59 ( ) 1.43 ( ) 1.64 ( ) 1.67 ( ) 1.0 ( ) 1.43 ( ) 379/2,636 better (14.4) better 1.0 ( ) 39/108 (38.1) 1.37 ( ) Mortality logarithmic scale
22 Why is Surgical Revascularization More Effective Than? More Complete Less Negative impact on native vessel Better patency (ITA) Improved vein graft function More protection against progression of atherosclerosis
23
24 Lesions Causing Clinical Event % Hazard Rate Non-Target Lesion Event Target Lesion Event Cutlip et al: Circ Year
25 What about simpler 3VD? has not been shown to prolong survival rate except for AMI Syntax has a 4 year F/U Curves are still diverging
26
27
28 Surgery and are not equivalent treatments, and the differences are not just completeness of revascularization
29 Multivessel Treatment There is no evidence that stenting prolongs the life expectency of any patient with chronic coronary artery disease. There is evidence that surgery does prolong the life expectency of some patients with CAD When we think prognosis is the issue, surgery should be the choice
30 Multivessel Paradigm Intervention until it is no longer possible, then surgery Surgery with intervention used to treat progression of disease
31 Follow-up (year) Survival - MVD Favors PTCA p=0.018 Favors Survival Risk Difference (%) JACC: 2003
32
PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationPCI vs. CABG for Left Main Disease
The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationUniversity of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
More informationLEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
More informationIs Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationCopenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationMajestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
More information06 Validation of risk prediction model
HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via
More informationCOMMON METHODOLOGICAL ISSUES FOR CER IN BIG DATA
COMMON METHODOLOGICAL ISSUES FOR CER IN BIG DATA Harvard Medical School and Harvard School of Public Health sharon@hcp.med.harvard.edu December 2013 1 / 16 OUTLINE UNCERTAINTY AND SELECTIVE INFERENCE 1
More informationMattias Törnerud, Capio St Görans sjukhus AB, Stockholm. Invasiv tryckmätning FFR
Namn: Titel: Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm Invasiv tryckmätning FFR Har mo/agit förläsararvoden från St Jude Medical. Intrakoronar tryckmätning, FFR i daglig praxis 1000 angio
More informationAntonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
More informationMEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
More informationCoronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)
Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationFFR CT : Clinical studies
FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationRenovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
More informationHA Territory-wide PCI Audit 2003-05
HA Territory-wide PCI Audit 23-5 5 PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 26 Percutaneous Coronary Intervention Background HA AP target 2/3, coordinated by PCI Working
More informationProvider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469)
Provider Checklist-Outpatient Imaging Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469) Medical Review Note: Per InterQual, if any of the following are present,
More information2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
More informationHealth Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial
Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationNIHI Big Data in Healthcare Research Case Study
NIHI Big Data in Healthcare Research Case Study Professor Rob Doughty Heart Foundation Chair of Heart Health National Institute for Health Innovation and the Dept of Medicine, University of Auckland &
More informationJournal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.
Journal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01408-5 Prognostic
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationNon-invasive functional testing in 2014
Non-invasive functional testing in 2014 Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Disclosures: Research grants: Edwards and Siemens Non-invasive functional testing in 2014
More informationPatients with end-stage renal disease (ESRD) are at high
Long-Term Outcome of Renal Transplant Recipients in the United States After Coronary Revascularization Procedures Charles A. Herzog, MD; Jennie Z. Ma, PhD; Allan J. Collins, MD Background Retrospective
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationCardiovascular Disease and Diabetes Management of Chronic Coronary Disease
Cardiovascular Disease and Diabetes Management of Chronic Coronary Disease Donald E. Cutlip, MD Beth Israel Deaconess Medical Center Harvard Clinical Research Institute Harvard Medical School Diabetes
More informationOutcome of Coronary Bypass Surgery Versus Coronary Angioplasty in Diabetic Patients With Multivessel Coronary Artery Disease
10 CLINICAL STUDIES JACC Vol. 31, No. 1 INTERVENTIONAL CARDIOLOGY Outcome of Coronary Bypass Surgery Versus Coronary Angioplasty in Diabetic Patients With Multivessel Coronary Artery Disease WILLIAM S.
More informationIs it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationPresenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationTips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD
Tips for surviving the analysis of survival data Philip Twumasi-Ankrah, PhD Big picture In medical research and many other areas of research, we often confront continuous, ordinal or dichotomous outcomes
More information6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
More informationStent for Life Initiative How can we improve system delay and patients delay in STEMI
Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration
More informationMADIT-II CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY MADIT-II Boston Scientific Corporation
More informationDo método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez
Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos Eulógio E Martinez IVUS vs luminologia Positivo Negativo estenose TCE oclusão CD sístole
More informationThe optimal treatment of multivessel coronary artery disease
The optimal treatment of multivessel coronary artery disease The time of ad hoc angioplasty for the patient with multivessel coronary artery disease has passed. James Wilson, Texas Heart Institute. Alexander
More information4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts
Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More informationRenal artery stenting: are there any indications left?
there any indications left? Luís Mendes Pedro, MD. PhD, FEBVS Lisbon Academic Medical Centre (University of Lisbon and Hospital Santa Maria) Instituto Cardiovascular de Lisboa Disclosures Speaker name:
More informationESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease. Erich Minar Medical University Vienna
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease Erich Minar Medical University Vienna for the Task Force on the Diagnosis and Treatment of Peripheral
More informationEndoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter
Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter Endoskopische Venenentnahme (EVH) - Einführung 1979 Tevaearai und Kollegen haben
More informationClinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
More informationThe Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs
The Role of Insurance in Providing Access to Cardiac Care in Maryland Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs Heart Disease Heart Disease is the leading cause of death
More informationDrug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate
Drug-Eluting Coronary Stents Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate Outline Coronary Artery Disease Evolution of Percutaneous Coronary Intervention
More informationCardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease
Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification
More informationCardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology
Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology Chapter 4: Endocrine, Nutritional, and Metabolic Diseases (E00-E89) The diabetes mellitus codes are combination codes
More informationThe Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
More informationUtilizing the Cath Lab for Cardiac Arrest
Utilizing the Cath Lab for Cardiac Arrest Khaled M. Ziada, MD Director, Cardiovascular Catheterization Laboratories Gill Heart Institute, University of Kentucky UK/AHA Strive to Revive Symposium May 2013
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationSuccess factors in Behavioral Medicine
Success factors in Behavioral Medicine interventions post myocardial infarction Depression Gunilla post myocardial Burell, PhD infarction Department of Public Health, Uppsala University, Sweden XIII Svenska
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationCHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99) March 2014 2014 MVP Health Care, Inc. CHAPTER 9 CHAPTER SPECIFIC CATEGORY CODE BLOCKS I00-I02 Acute rheumatic fever I05-I09 Chronic rheumatic heart
More informationDatabases in Clinical Research. Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support
Databases in Clinical Research Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support Overview Background: History and utility of clinical data repositories Strategies:
More informationGreg Peterson, MPA, PhD candidate Melissa McCarthy, PhD Presentation for 2013 AcademyHealth Annual Research Meeting
Greg Peterson, MPA, PhD candidate Melissa McCarthy, PhD Presentation for 2013 AcademyHealth Annual Research Meeting Medicare Coordinated Care Demonstration (MCCD) Established in Balanced Budget Act of
More informationAndrogens and CVD. Brandon Orr- Walker April 2014
Androgens and CVD Brandon Orr- Walker April 2014 Agenda What is normal physiology of Aging? Hypogonadism and disease If some is good is more becer? CVD safety Clinical features of Androgen Deficiency
More informationVascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial
Vascular Quality Initiative - Carotid Artery Stent Last Name First Name Middle Initial Date of Birth Medical Record Social Security General Information Patient Data Zip/Postal Code Gender Male Female Ethnicity
More informationIntracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
More informationThe clinical outcome after coronary bypass surgery: a 30-year follow-up study
European Heart Journal (2009) 30, 453 458 doi:10.1093/eurheartj/ehn530 CLINICAL RESEARCH Coronary heart disease The clinical outcome after coronary bypass surgery: a 30-year follow-up study Ron T. van
More informationDrug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam
Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura
More informationImpact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care
Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care Michelle A. Albert MD MPH Treacy S. Silbaugh B.S, John Z. Ayanian MD MPP, Ann Lovett RN
More informationCARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN
HOSPITALIZATION CASE #: 2 8 8 0 H FY288BH4CN Has the participant indicated any of the following reasons for being admitted overnight for this case? 1. Suspected or confirmed problems with the heart, circulation,
More informationAortic Valve Stenosis and CAD
EUROECHO 14, Copenhagen 2010 Aortic Valve Stenosis and CAD Aleksandar N. Neskovic Clinical Hospital Center Zemun Belgrade University School of Medicine Aortic Stenosis and CAD Important facts Links AS/CAD
More informationGuidelines Most Significantly Affected Under ICD-10-CM. May 29, 2013
Guidelines Most Significantly Affected Under ICD-10-CM May 29, 2013 Guidelines Most Significantly Affected Under ICD-10-CM A look at the new system and how it compares to ICD-9-CM Presented by Therese
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationHow can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris
How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore
More informationAcute Coronary Syndrome. What Every Healthcare Professional Needs To Know
Acute Coronary Syndrome What Every Healthcare Professional Needs To Know Background of ACS Acute Coronary Syndrome (ACS) is an umbrella term used to cover a spectrum of clinical conditions that are caused
More informationWhat is a Heart Attack? 1,2,3
S What is a Heart Attack? 1,2,3 Heart attacks, otherwise known as myocardial infarctions, are caused when the blood supply to a section of the heart is suddenly disrupted. Without the oxygen supplied by
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationEvaluation of Predictive Models
Evaluation of Predictive Models Assessing calibration and discrimination Examples Decision Systems Group, Brigham and Women s Hospital Harvard Medical School Harvard-MIT Division of Health Sciences and
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationQuantifying Life expectancy in people with Type 2 diabetes
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
More informationFor the NXT Investigators
Diagnostic performance of non-invasive fractional flow reserve derived from coronary CT angiography in suspected coronary artery disease: The NXT trial Bjarne L. Nørgaard, Jonathon Leipsic, Sara Gaur,
More informationINTRODUCTION. Key Words:
Case Report Acta Cardiol Sin 2014;30:485 489 Successful Revascularization of Chronic Total Occlusion in Native Coronary Arteries through an Occluded Saphenous Bypass Vein Graft: A Retrograde Alternative
More informationManagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management
More informationDISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015
Death (%) Mortality (%) 9/16/2015 DISCLOSURE Atrial Fibrillation Management An Evidence-based Approach Jonathon Adams, MD, FHRS Relevant Financial Relationship(s) None Off Label Usage None OBJECTIVES What
More informationVitamin D and Cardiometabolic risk
Vitamin D and Cardiometabolic risk 서울의대, 분당서울대병원 내과 최 성 희 2013년 대한당뇨병학회 춘계학술대회 Metabolism Of Vitamin D Risk factors for vitamin D deficiency - Aging decreased concentrations of 7-dehydro-cholesterol in
More informationThe Critical Importance of Targeting (or It s the targeting, stupid. )
The Critical Importance of Targeting (or It s the targeting, stupid. ) Randall Brown NHPF Targeting High-Cost Medicare Beneficiaries to Improve Care and Reduce Spending: Finding the Bull's-Eye March 9,
More informationCARDIOVASCULAR PROBLEMS IN SURVIVORS OF CHILDHOOD CANCER AND THEIR SIBLINGS
Swiss Childhood Cancer Registry (SCCR) CARDIOVASCULAR PROBLEMS IN SURVIVORS OF CHILDHOOD CANCER AND THEIR SIBLINGS Julien Caccia, Corina S. Rueegg, Eva-Maria Hau, Nicolas X. von der Weid, Gisela Michel,
More informationKawasaki Disease Complicated by Coronary Artery Aneurysms: Mortality and 40-year Outcomes
Kawasaki Disease Complicated by Coronary Artery Aneurysms: Mortality and 40-year Outcomes C. Manlhiot, A. Crean, N. Fernandopulle, B. Lew, N. Chahal, B.W. McCrindle Division of Cardiology, Department of
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.1056/NEJMSA1107913 Niteesh K. Choudhry, MD, PhD, 1 Jerry Avorn, MD, 1 Robert J. Glynn,
More informationRepresentative market data weighted to reveal insights. A multifaceted view of actual vs. expected claims
Critical illness insurance in Israel The Munich Re Biometric Critical Illness Study 2010 A unique biometric Critical Illness study Munich Re has conducted a comprehensive study of critical illness insurance
More information